OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
Surgical Treatment of Lung Cancer: Defining Resectability in the Immunotherapy Era

Surgical Treatment of Lung Cancer: Defining Resectability in the Immunotherapy Era

by Nuria María Novoa | 29 January 2025 | Lung Cancer

Thanks to the implementation of neoadjuvant immunotherapy, new horizons have opened up with respect to the limits of surgical tumor resection in patients with lung cancer. However, technical problems need to be addressed, and there is great variability regarding the...
New Perspectives In The Early And Late Stages Of Cervical Cancer

New Perspectives In The Early And Late Stages Of Cervical Cancer

by Apostolos Sarivalasis | 22 January 2025 | Women's Cancers

As with other types of cancer, the therapeutic landscape for cervical cancer has been transformed by immunotherapy, but changes are taking place in various strategic areas. Innovative approaches are expanding the algorithms for locally advanced and metastatic disease....
FDA Approves Dato-DXd for Advanced HR-Positive, HER2-Negative Breast Cancer

FDA Approves Dato-DXd for Advanced HR-Positive, HER2-Negative Breast Cancer

by FDA Approval | 20 January 2025 | Women's Cancers

On January 17, 2025, the US Food and Drug Administration (FDA) approved datapotamab deruxtecan-dlnk (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human...
FDA Approves Sotorasib & Panitumumab Combination for KRAS G12C-Mutated Metastatic Colorectal Cancer

FDA Approves Sotorasib & Panitumumab Combination for KRAS G12C-Mutated Metastatic Colorectal Cancer

by FDA Approval | 17 January 2025 | Gastrointestinal

On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved the combination of sotorasib and panitumumab for treating adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC). This approval applies to patients who have undergone prior...
Debate: Continuous Vs. Fixed-duration Immunotherapy

Debate: Continuous Vs. Fixed-duration Immunotherapy

by PEAK Medicals | 9 January 2025 | Lung Cancer

Written by Giannis Mountzios, MD PhD and Sandip Patel, MD.   Immune checkpoint inhibition has revolutionized lung cancer care. However, the question of optimal treatment duration is still unanswered. Can treatment benefits be maximized by prolonged immunotherapy...
« Older Entries
Next Entries »

Recent Posts

  • Swissmedic Approvals Expand Options for HR+ Metastatic Breast Cancer: Trastuzumab Deruxtecan and Datopotamab Deruxtecan
  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer
  • Endometrial Cancer: A Revolution That Is Only Just Beginning

Recent Comments

  1. Swissmedic Approvals Expand Options for HR+ Metastatic Breast Cancer: Trastuzumab Deruxtecan and Datopotamab Deruxtecan | OncoViews on Breast Cancer Subtype Definitions (1/4)

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}